Paclitaxel Device Prognosis; PCSK9 Now Cost Effective; ICU Benefit in STEMI?
Recent developments of interest in cardiovascular medicine
The FDA posted materials ahead of its June 19-20 advisory committee meeting on mortality risk of paclitaxel-coated stents and balloons for peripheral use; an Investor's Business Daily analyst said they suggest the agency won't pull the devices from the market but could call for more studies. Watch for MedPage Today's coverage onsite next week.